MedTrace Logo

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

NCT01592292 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2016-08-22

Study results available
· View outcomes & findings →

Summary

This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF alpha therapy. Participants have commenced MabThera or an alternative anti-TNF alpha treatment as a second biological therapy. Data will be collected for 12 months.

Conditions

Interventions

DRUG

Rituximab

Rituximab as per physician's discretion.

DRUG

Adalimumab

Adalimumab as per physician's discretion.

DRUG

Etanercept

Etanercept as per physician's discretion.

DRUG

Infliximab

Infliximab as per physician's discretion.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01592292 on ClinicalTrials.gov